Literature DB >> 23880917

Genetic characteristics of Neisseria meningitidis serogroup B strains carried by adolescents living in Milan, Italy: implications for vaccine efficacy.

Susanna Esposito1, Alberto Zampiero, Leonardo Terranova, Valentina Montinaro, Alessia Scala, Valentina Ansuini, Nicola Principi.   

Abstract

Before a protein vaccine is introduced into a country, it is essential to evaluate its potential impact and estimate its benefits and costs. The aim of this study was to determine the genetic characteristics of Neisseria meningitidis B (NmB) in the pharyngeal secretions of 1375 healthy adolescents aged 13-19 y living in Milan, Italy, in September 2012, and the possible protection offered by the two currently available NmB protein vaccines. Ninety-one subjects were Nm carriers (6.6%), 29 (31.9%) of whom carried the NmB capsular gene. The 29 identified strains belonged to eight clonal complexes (CCs), the majority of which were in the ST-41/44/Lin.3 CC (n = 11; 37.9%). All of the identified strains harboured ƒHbp alleles representing a total of 15 sub-variants: the gene for NHBA protein was found in all but three of the studied strains (10.3%) with 13 identified sub-variants. There were 15 porA sub-types, seven of which were identified in just one CC. The findings of this study seem to suggest that both of the protein vaccines proposed for the prevention of invasive disease due to NmB (the 4-protein and the 2-protein products) have a composition that can evoke a theoretically effective antibody response against the meningococcal strains currently carried by adolescents living in Northern Italy. The genetic characteristics of NmB strains can be easily evaluated by means of molecular methods, the results of which can provide an albeit approximate estimate of the degree of protection theoretically provided by the available vaccines, and the possible future need to change their composition.

Entities:  

Keywords:  Neisseria meningitides; invasive bacterial disease; meningococcal vaccine; meningococcus B; meningococcus B vaccine

Mesh:

Substances:

Year:  2013        PMID: 23880917      PMCID: PMC3981836          DOI: 10.4161/hv.25800

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  38 in total

1.  Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa.

Authors:  Kedibone M Mothibeli; Mignon du Plessis; Anne von Gottberg; Ellen Murphy; Susan K Hoiseth; Gary Zlotnick; Keith P Klugman
Journal:  Vaccine       Date:  2010-12-07       Impact factor: 3.641

2.  Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1.

Authors:  Brunella Brunelli; Elena Del Tordello; Emmanuelle Palumbo; Alessia Biolchi; Stefania Bambini; Maurizio Comanducci; Alessandro Muzzi; Mariagrazia Pizza; Rino Rappuoli; John J Donnelly; Marzia M Giuliani; Davide Serruto
Journal:  Vaccine       Date:  2010-12-03       Impact factor: 3.641

3.  Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.

Authors:  Nicoletta Gossger; Matthew D Snape; Ly-Mee Yu; Adam Finn; Gianni Bona; Susanna Esposito; Nicola Principi; Javier Diez-Domingo; Etienne Sokal; Birgitta Becker; Dorothee Kieninger; Roman Prymula; Peter Dull; Ellen Ypma; Daniela Toneatto; Alan Kimura; Andrew J Pollard
Journal:  JAMA       Date:  2012-02-08       Impact factor: 56.272

4.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods.

Authors:  Koichiro Tamura; Daniel Peterson; Nicholas Peterson; Glen Stecher; Masatoshi Nei; Sudhir Kumar
Journal:  Mol Biol Evol       Date:  2011-05-04       Impact factor: 16.240

Review 5.  The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens.

Authors:  Davide Serruto; Matthew J Bottomley; Sanjay Ram; Marzia M Giuliani; Rino Rappuoli
Journal:  Vaccine       Date:  2012-05-30       Impact factor: 3.641

6.  Evaluation of the Applied Biosystems automated Taqman polymerase chain reaction system for the detection of meningococcal DNA.

Authors:  M Guiver; R Borrow; J Marsh; S J Gray; E B Kaczmarski; D Howells; P Boseley; A J Fox
Journal:  FEMS Immunol Med Microbiol       Date:  2000-06

7.  Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.

Authors:  M L Tondella; T Popovic; N E Rosenstein; D B Lake; G M Carlone; L W Mayer; B A Perkins
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

8.  Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.

Authors:  Helen S Marshall; Peter C Richmond; Michael D Nissen; Qin Jiang; Annaliesa S Anderson; Kathrin U Jansen; Graham Reynolds; John B Ziegler; Shannon L Harris; Thomas R Jones; John L Perez
Journal:  Pediatr Infect Dis J       Date:  2012-10       Impact factor: 2.129

9.  Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.

Authors:  Timo Vesikari; Susanna Esposito; Roman Prymula; Ellen Ypma; Igor Kohl; Daniela Toneatto; Peter Dull; Alan Kimura
Journal:  Lancet       Date:  2013-03-09       Impact factor: 79.321

10.  Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease.

Authors:  Annaliesa S Anderson; Li Hao; Qin Jiang; Shannon L Harris; Thomas R Jones; John L Perez; Laura York; Joseph Eiden; Kathrin U Jansen
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

View more
  1 in total

1.  Neisseria meningitidis serogroup B carriage by adolescents and young adults living in Milan, Italy: Prevalence of strains potentially covered by the presently available meningococcal B vaccines.

Authors:  Leonardo Terranova; Nicola Principi; Sonia Bianchini; Giada Di Pietro; Giulia Umbrello; Barbara Madini; Susanna Esposito
Journal:  Hum Vaccin Immunother       Date:  2018-05-09       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.